The present article reviews the evidence that melatonin possesses sleep-inducing effects and that it gates the increase in nocturnal sleepiness. It is shown that, without exception, all the studies that have investigated daytime administrations of melatonin reported increased sleepiness, even at doses that do not increase plasma levels of melatonin beyond its physiological levels. By contrast, nighttime increase in sleepiness was achieved only after administration of high doses. Based on these findings and on the precise coupling between the endogenous nocturnal increase in melatonin secretion and the opening of the sleep gate, it is suggested that melatonin participates in the regulation of the sleep-wake cycle by inhibiting the central nervous system wakefulness generating system. This inhibition allows a smooth transition from wakefulness to sleep. Clinical findings on decreased levels of nocturnal melatonin in chronic insomniacs, and on the efficacy of exogenous melatonin in improving sleep in melatonindeficient insomniacs, are congruent with this hypothesis.
Introduction
If one had to guess which one of the brain hormones is involved in sleep regulation just from its 24-h pattern of secretion, then melatonin no doubt would be a prime candidate. What could be a better agent to regulate sleep than a brain substance exclusively produced and secreted during the dark hours? In humans, the circadian cycle in melatonin production and secretion is closely associated with the sleep-wake cycle. The rise in nocturnal melatonin precedes the conventional time for sleep, its peak occurs during the sleep period, and its decline coincides with waking up from sleep. Not surprisingly, ever since its isolation (Lerner et al., 1958) , it was speculated that melatonin is not only the &dquo;darkness hormone&dquo; but also the &dquo;tranquilizing hormone.&dquo; The first reports showing that melatonin possesses sleep-inducing effects were conducted in animals (Marczynski et al., 1964) . Soon after that appeared the first human studies. Anton-Tay et al. (1971) reported that intravenous injections of 0.25 to 1.25 mg/kg melatonin to normal volunteers at 1600 h caused an increase in alpha activity and in electroencephalogram (EEG) synchronization and that the subjects fell asleep 15 to 20 min later. Two years later, Cramer et al. (1973) showed that an intravenous injection of 50 mg melatonin at 2130 h significantly shortened sleep latency in normal young adults without affecting sleep structure.
The purpose of the present article is to review the evidence that melatonin possesses sleep-inducing effects and to examine the possible role of endogenous melatonin in sleep regulation. Based on recent data from our laboratory, I suggest that the endogenous rise in nocturnal secretion of melatonin gates the increase in nocturnal sleep propensity and, as such, participates in the sleep-wake cycle regulation. The potential therapeutic use of melatonin is discussed in light of its proposed role in gating nocturnal sleepiness. The article does not discuss melatonin's phase-shifting effects, which are reviewed by Sack and Lewy (1997) , Redman (1997) , and Arendt et al. (1997) in this issue.
Nighttime and Daytime Administration
Studies investigating the possible sleep-inducing effects of melatonin differ widely from each other with respect to the subjects (normal adults or insomniacs), the dosage (from 0.1 to 1000 mg), the route of administration (intravenous injection, nasal, or oral routes), and the time of administration (day or night). Among all these variables, the time of administration appears to be the most crucial factor with respect to melatonin's sleep-inducing effects. Time of administration is important for two reasons. First, because in humans melatonin is secreted exclusively during the night, daytime and nighttime administrations of exogenous melatonin result in widely different blood levels of the hormone as well as widely different ratios of existing circulating levels at the time of administration to the exogenously added melatonin. When melatonin is administered after the nocturnal rise of its endogenous secretion, it is superimposed on previously elevated levels of the hormone. During the daytime, when there is no circulating melatonin (or very little), the administration of exogenous melatonin, even at low dosages, produces nighttime levels of the hormone (or higher). Second, because the main outcome variable in studies investigating possible sleep-inducing effects of melatonin is an increase in sleepiness, the effect of nighttime administration is bounded by the endogenous increase in nocturnal sleepiness. Thus, it can be expected that nighttime and daytime administration would produce different results.
In studies investigating nighttime administration of melatonin, only high pharmacological doses provided evidence that supports the notion of sleep-inducing effects. As mentioned previously, Cramer et al. (1973) injected 50 mg melatonin intravenously during the day and night. A nighttime injection at 2130 h decreased sleep latency from 23.3 min in the placebo condition to 10.4 min. No other changes in sleep structure were found, and there were no significant effects on subjective sleep quality. Daytime injections induced sleep within 15 to 40 min, and each sleep episode lasted 26 to 60 min. In a study designed to investigate the effects of a variety of pharmacological treatments on experimentally induced insomnia by exposure to tape-recorded traffic noise, Waldhauser et al. (1990) examined the effects of a single 80-mg melatonin administration on polysomnographically determined sleep. Melatonin administered at 2100 h, 11h hours before bedtime, significantly decreased sleep latency and improved sleep efficiency. MacFarlane et al. (1991) treated 13 chronic insomniacs in a doubleblind, placebo-controlled experiment with 75 mg melatonin administered at 2200 h for 7 days. A significant increase in questionnaire-determined total sleep time and improvement in daytime alertness was reported. Although improved sleep was evident from the first night of treatment, there also was a nonsignificant trend for the maximum response to melatonin to be delayed by 2 to 3 days. Nocturnal administration of low-dose melatonin, although still in the pharmacological range, did not yield the same effects. James et al. (1987) administered either 1 or 5 mg melatonin or placebo in a doubleblind, crossover design to 10 normal subjects. Treatment was administered at 2245 h, 15 min before the lights were turned off. The only significant effect was a prolongation of rapid eye movement (REM) latency in the melatonin condition. The same group also reported lack of effects of the same dosages on polysomnographically recorded sleep in subjects with psychophysiological insomnia. There was a minor subjective improvement in sleep quality (James et al., 1990 ). Ellis et al. (1996) , however, did not observe any melatonin effect on subjective sleep quality in insomniacs.
The results of studies in which melatonin was administered during the day produced far more consistent results for both high and low dosages. Lieberman et al. (1984) administered three oral doses of 80 mg melatonin at 1200, 1300, and 1400 h on one day and three placebo treatments on another day. Melatonin significantly altered various aspects of self-reported mood and performance in a manner similar to changes produced by hypnotic drugs. Nickelsen et al. (1989) administered (orally) 50 mg melatonin in a doubleblind, placebo-controlled study at either 0900 or 1900 h for 7 days. There were significant effects on self-rated sleepiness and tiredness for the morning administration. Although subjects receiving melatonin showed decreased nocturnal sleep latencies, as indicated by questionnaires, this change was not statistically significant. Dollins et al. (1993) administered 10, 20, 40, or 80 mg melatonin at 1145 h and reported that all dosages increased the scores on the Stanford Sleepiness Scale as well as feelings of fatigue, whereas they de-creased performance levels in a manner similar to drugs with sedative-like properties.
Similar effects also were reported for daytime administration of much lower dosages. Vollrath et al. (1981) administered 1.7 mg melatonin as a nasal spray to healthy young adults at 0900 to 1000 h and reported that within 40 to 60 min postadministration, 7 of the 10 subjects fell asleep; approximately 1 h later, 2 more fell asleep. In addition, 1 subject fell asleep in the placebo condition. Unfortunately, no objective monitoring of sleep was carried out in this study Arendt et al. (1984) investigated the effects of 2 mg melatonin administered for 4 weeks at 1700 h on self-rated mood and fatigue assessed at 0800, 1200, 1900, and 2200 h and on subjectively assessed nocturnal sleep quality.
The most consistent effect was an increased sensation of tiredness at 1900 and 2200 h. The effect on tiredness became significant 5 days after the start of treatment. Arendt et al. suggested that the slow onset of increased evening tiredness was more consistent with an effect on the timing mechanism of sleep than with an acute sleep-inducing effect. However, they did not rule out the possibility of a progressive sensitization to melatonin. Significant effects of a single administration of 5 mg melatonin at 1300 or 1800 h on subjective sleepiness and on waking EEG power density in the theta/alpha range were reported by Cajochen et al. (1996) . The increase in sleepiness appeared 40 and 90 min after the administration, whereas the effects on the EEG appeared almost immediately. administered either 0.1 or 0.3 mg melatonin or placebo at 1800, 2000, or 2100 h in a double-blind, crossover paradigm. Lights were turned off 1 or 2 h following administration. Both doses of melatonin, at all times of administration, significantly decreased sleep latency. Nave et al. (1996) investigated the effects of 3 mg melatonin administered at 1200 h on sleep propensity monitored polysomnographically until 1900 h. Melatonin significantly decreased the latency to the first appearance of sleep, increased the amount of total sleep throughout the recording period, and decreased core body temperature. Neither the sleep-inducing effect nor the hypothermic effect of melatonin was antagonized by flumazenil, a pure central benzodiazepine antagonist. A similar study was performed by Reid et al. (1996) (1995) reported that 5 mg melatonin administered 30 min before a daytime nap from 1300 to 1700 h enhanced the EEG power density in non-REM sleep in the 13.75to 14.00-Hz bin. During the first 2 h of the nap, melatonin also reduced the power density in the low-frequency range of 2.25 to 5.00 Hz. Because subjects were partially sleep deprived prior to the daytime nap, there were no effects on sleep latency or on sleep efficiency. In their study on the effects of 3 and 6 mg melatonin on an evening nap, Lavie et al. (in press) also investigated its effects on the non-REM EEG spectra. In agreement with Dijk et al. (1995) , they reported that both dosages of melatonin significantly enhanced the power density in the sigma range of 11.25 to 14.00 Hz, whereas the low dose suppressed the power in the low-frequency range of 1.0 to 5.5 Hz, particularly during the 2nd hour of the nap. The findings of a tendency toward suppression of delta activity are congruent with the results of Hughes and Badia (1997) that 1, 10, and 40 mg melatonin administered before a 4-h daytime nap suppressed sleep Stages 3 and 4.
The enhancement effects of melatonin on the EEG power density in the sigma range and its suppression effects in the low-frequency range are consistent with the effects of hypnotics that are GABA,-benzodiazepine receptor agonists. This may lead to the suggestion that melatonin's hypnotic effects are exerted through the same mechanism. Reports that melatonin modifies GABA-ergic neural transmission also support this assertion (e.g., Stankov et al., 1992) . Our findings, however, that flumazenil, a pure antagonist of the central benzodiazepine receptors, did not block the sleep-inducing effects of melatonin (Nave et al., 1996) weaken this hypothesis. It is possible, however, that a unique subtype of the GABAA-benzodiazepine receptor complex is involved in mediating melatonin effects.
In summary, although high pharmacological levels of melatonin were needed to show hypnotic effects during the nighttime, all of the studies in which melatonin was administered during the daytime successfully demonstrated increased sleepiness. This was seen even at doses as low as 0.1 and 0.3 mg, which do not raise plasma melatonin levels beyond melatonin's nocturnal physiological levels. These effects, however, were not immediate; rather, they appeared to build up gradually over 1 to 3 h, depending on the precise time of administration. At least one study (Cajochen et al., 1996) showed that the sleep-inducing effects may appear earlier in the EEG than in subjective indexes of sleepiness, thus suggesting that melatonin may affect brain structures related to arousal at different rates.
The hypothermic effects that also were consistently shown after melatonin administration led several investigators to suggest that they may be related to melatonin's sleep-promoting effects. Comparison of the time courses of increased sleepiness and the hypothermic effects may provide important information needed to evaluate this hypothesis. The similarities between the effects of melatonin on EEG power spectra and on sleep Stages 3 and 4 and those of GABAA benzodiazepine receptors' agonists leave open the possibility that the GABA,-benzodiazepine receptor complex or one of its subtypes is involved in mediating melatonin sleep-inducing effects.
Melatonin and Sleep Propensity
Is it possible to deduce the potential role of endogenous melatonin in sleep regulation from the observed effects of exogenous melatonin? The consistent effects of daytime administration of melatonin on sleepiness raise the possibility that the endogenous daily cycle in melatonin secretion is gating the nocturnal rise in sleep propensity. To test this hypothesis, we investigated the circadian patterns of sleep propensity by means of an ultra-short sleep-wake paradigm, the &dquo;7/13&dquo; sleep-wake paradigm, concomitantly with the measurement of the circadian rhythm in urinary excretion of 6-sulfamethoxymelatonin (aMT6s), the major urinary metabolite of melatonin (Tzischinsky et al. 1993 ). The 7/13 paradigm consists of 20-min trials, performed repeatedly for 24 h, in which the maximum amount of sleep permitted per trial is 7 min. The total amount of sleep obtained in each trial is plotted to provide the sleep propensity function (SPF), which describes the speed of falling asleep across the 24 h (Lavie, 1986 ). The temporal shape of the SPF is characterized by two distinct features. In the early evening, there is a clear nadir in sleepiness. This period was labeled the &dquo;forbidden zone&dquo; for sleep. Subsequently, there is an abrupt change in sleep latency during what was termed the &dquo;primary nocturnal sleep gate.&dquo; In many subjects, the opening of the sleep gate marks an abrupt transition from a period of low sleep propensity to a period of high sleep propensity that persists throughout the night period. In some of the subjects, there also is a midafternoon period of increased sleepiness, secondary to the primary nocturnal crest. Supporting our prediction that the nocturnal rise in melatonin secretion gates the &dquo;opening&dquo; of the nocturnal sleep gate, we found a significant correlation between the nocturnal onset of aMT6s secretion (mean time 2145 ± 2.38 h) and the time of the sleep gate (mean time 2334 ± 2.39 h). Shochat et al. (1997) repeated the same study with measurements of plasma levels of melatonin during each of the 13-min intervening wake periods during the 7/13 paradigm. They showed that the increase in nocturnal melatonin secretion was phase-locked to the opening of the primary nocturnal sleep gate. This is exemplified in Fig. 1 . In all subjects, the onset of nocturnal melatonin secretion starts during the middle of the forbidden zone for sleep, preceding the sleep gate by approximately 100 min. Furthermore, the onset of melatonin secretion coincided with the peak in core body temperature. Exposing subjects to 2 h of bright light at the time of onset of the nocturnal rise in melatonin, or administering melatonin during the evening preceding the 7/13 paradigm, did not alter these phase relationships.
Further support for the existence of a precise phase relationship between the sleep gate and the nocturnal rise in melatonin secretion was provided by investi- Figure 1 . Sleep propensity measured by the ultra-short sleep-wake 7/13 paradigm (7 min sleep, 13 min wake) from 0700 to 0200 h and plasma melatonin level measured every 20 min in 2 representative subjects (12a and 7a). Each point represents total sleep time (TST) for a given 7-min sleep attempt in each trial. gating the relationship between melatonin secretion and sleep propensity in cases with altered circadian rhythmicity. Nakagawa et al. (1992) studied a blind man whose sleep propensity rhythm, as determined by the 7/13 paradigm once a week for 4 weeks, free ran. They reported that the nocturnal onset of melatonin was phase-locked with the sleep gate, preceding it by 2.6 h. Similar results also were reported in a sighted man with a non-24-h sleep-wake syndrome who was investigated in a similar manner by McArthur et al. (1996) . The onset of melatonin secretion in this patient occurred 90 min before the opening of the sleep gate. The association between increased sleep propensity and endogenous rise in melatonin secretion also was found in a napping pattern of blind people whose melatonin rhythms free ran . The timing of their daytime naps was consistent with the deviations in the melatonin rhythms, with most naps occurring within 5 h before or after the peak secretion.
If the onset of nocturnal melatonin gates the nocturnal rise in sleepiness, then it can be expected that daytime administration of melatonin would alter the shape of the SPF in a systematic way. Tzischinsky and Lavie (1994) investigated this question by administering 5 mg melatonin or placebo at four different times: 1200, 1700, 1900, and 2100 h. Compared to an all-placebo condition, melatonin altered the shape of the SPF in a time dependent manner. Administration of mela-tonin at 1200 h considerably augmented the midafternoon sleepiness peak and delayed the sleep gate from 2240 to 2400 h. Administrations at 1700,1900, and 2100 h significantly advanced the time of the gate. Figure 2 contrasts the effects of administering melatonin at 1200 and 2100 h in a representative subject. The observed changes in the timing of the sleep gate after daytime administrations of melatonin resemble its phase response curve with regard to its own endogenous production, the phase delay of endogenous melatonin production in response to morning-midday administrations, and the phase advance in response to afternoon-evening administrations . Thus, the observed changes in the timing of the sleep gate probably reflect the underlying changes in the onset of endogenous melatonin secretion. Unfortunately, we did not measure the level of melatonin in that study, which would have enabled us to corroborate this explanation.
Inducing Sleep or Shutting off Wakefulness
Based on our findings regarding the relationship between the endogenous secretion of melatonin and the opening of the nocturnal sleep gate, and the relationship between the onset of nocturnal melatonin secretion and the peak in core body temperature, we proposed that the role of melatonin in the induction of sleep is to inhibit the wakefulness-producing mecha- Figure 2 . Sleep propensity measured by the ultra-short sleep-wake 7/13 paradigm (7 min sleep,13 min wake) from 0700 to 0700 in 1 subj ect under placebo (closed circles) and under 5 mg melatonin (open circles) administered at 1200 or 2100 h (light line). Each point represents total sleep time (TST) for a given 7-min sleep attempt in each trial. nisms in preparation for activation of somnogenic structures (Shochat et al., 1997) . This hypothesis was based on the following considerations.
As described previously, the opening of the sleep gate is preceded by a period of increased arousal-the forbidden zone for sleep or the wakefulness maintenance zone-that is abruptly terminated by the opening of the sleep gate. This zone of increased arousal probably represents the peak of a 24-h rhythm in arousal that is represented by the underlying changes in core body temperature. Evidence of the existence of a circadian cycle in arousal that peaks just before the sleep gate was provided by Dijk and Czeisler (1995) and by Edgar et al. (1993) . Based on their results with the forced desynchrony protocol, Dijk and Czeisler (1995) concluded, The signal which promotes wakefulness gradually becomes stronger on the rising limb of the endogenous rhythm of core body temperature, with a maximum at approximately 240°, which corresponds to the evening wake maintenance zone (Strogatz et al., 1986) and the so-called &dquo;forbidden zone for sleep (Lavie, 1986) .&dquo; (p. 3534) Dijk and Czeisler (1995) suggested that the variations in the output of the suprachiasmatic nucleus (SCN) are responsible for the circadian cycles in sleep propensity. Evidence for the involvement of the SCN in the regulation of the circadian cycles in arousal was provided by Edgar et al. (1993) . They investigated sleep-wake cycles in SCN-lesioned squirrel monkeys and concluded that two opponent physiological processes are responsible for the regulation of the sleepwake cycle; one promotes wakefulness, and the other, a homeostatic process, increases the sleep drive. The site of the wakefulness-regulating mechanism was suggested to be in the SCN. Thus, both the animal data and human data provide evidence that there is a circadian cycle in arousal independent of the homeostatic sleep drive, which paradoxically peaks just before the onset of nocturnal sleep propensity-the sleep gate. Therefore, we suggested that the onset of melatonin secretion that coincides with the peak of the arousal cycle inhibits the wakefulness-generating mechanism, thus enabling the brain's somnogenic structures to be activated-unopposed by the waking mechanisms. This ensures a smooth wake-to-sleep transition. The effects of melatonin on the SCN wakefulness generator probably are mediated by the SCN melatonin receptors recently demonstrated in humans (Dubocovich, 1995) .
The fact that melatonin is involved in sleep regulation by shutting off wakefulness, rather than by actively inducing sleep, may explain some of the experimental findings concerning its sleep-inducing effects. First, it is compatible with the subjective experience of taking melatonin, which has been described as increased sensations of fatigue and readiness to fall asleep. Second, it is congruent with the observation that melatonin reaches its maximum sleep-inducing effects after a time period that is much longer than its relatively brief half-life. Furthermore, the 1to 3-h lag to maximal effect is congruent with our finding that the &dquo;opening&dquo; of the nocturnal sleep gate lags behind the endogenous onset of nocturnal secretion by 1.5 to 2.0 h. Cajochen et al. (1996) showed that changes in the EEG that are indicative of increased sleepiness appeared almost immediately after melatonin administration, whereas the subjective feelings of sleepiness appeared only 1 to 2 h later. This finding may suggest that the rise in nocturnal melatonin initiates a cascade of events involving diverse brain systems that eventually result in a widespread modification in central nervous system activity favoring sleep over wakefulness.
Clinical Implications
If the secretion of endogenous melatonin is involved in gating the nocturnal increase in sleepiness, then it can be expected that alterations in nocturnal increase in melatonin would interfere with sleep initiation. Some clinical data support such an association. Several studies demonstrated low levels of nocturnal melatonin secretion in insomnia. Haimov et al. (1994) reported that elderly insomniacs whose subjective complaints were validated by actigraphic monitoring had lower and delayed nocturnal peaks of aMT6s secretion. Peak excretion in similar-age elderly subjects without sleep disorders did not differ from that in young adults. The lowest nocturnal excretion of aMT6s, at an almost undetectable level, was found in elderly insomniacs who resided in a nursing home. Similar results were reported in middle-aged chronic primary insomniacs (Hajak et al., 1995) . Patients with long-term sleep maintenance problems (2:: 5 years) showed a decrease in nocturnal plasma melatonin levels. Likewise, Attenburrow et al. (1996) showed that primary insomniacs who suffered from sleep disorders for a mean of 18 years had lower evening plasma melatonin levels than did controls.
The data supporting the participation of melatonin in gating nocturnal sleep propensity, on the one hand, and the association between suppression of nocturnal secretion and insomnia, on the other, led to the possibility that exogenous melatonin may have a beneficial effect on insomnia associated with deficient levels of melatonin. Preliminary evidence supports this eventuality. Etzioni et al. (1996) treated a melatonin-defi-cient child who suffered from severe insomnia with 3 mg melatonin administered 2 h before the desired bedtime. Melatonin restored sleep to its normal duration and efficiency. These effects were evident during the 1st night of treatment. Likewise, restoring nocturnal melatonin levels in melatonin-deficient elderly insomniacs significantly improved their sleep (Haimov et al., 1995) , as 2 mg melatonin administered either as fastor sustained-release formulations improved actigraphically monitored sleep in comparison to placebo. A 1-week treatment with the 2-mg sustained-release formula was effective on sleep maintenance, whereas sleep initiation was improved after a 1-week treatment with fast-release melatonin.
An open study with 1 mg of sustained-release melatonin further improved sleep quality in these subjects. These results were later confirmed by Garfinkel et al. (1995) . They treated melatonin-deficient elderly patients, who were complaining of insomnia and also were receiving various treatments for chronic illnesses, with 2 mg of slow-release melatonin for 3 weeks. In agreement with Haimov et al. (1995) , they showed a significant increase in actigraphically monitored sleep efficiency and only a borderline significant effect on sleep latency Wurtman and Zhdanova (1995) reported that they achieved improvement in sleep quality and shortening of sleep latency in elderly insomniacs with 0.3 mg melatonin, which restored normal physiological melatonin levels.
Safety and Possible Side Effects
Preliminary results concerning the possible therapeutic effects of melatonin in melatonin-deficient patients appear promising and no doubt contributed to the worldwide interest in melatonin and its therapeutic potential. In view of the melatonin &dquo;craze,&dquo; it is surprising how little research has been done to determine its safety in long-term use and possible side effects. Lerner and Nordlund (1978) summarized all that was known on the effects of melatonin administered to humans. At that time, approximately 100 people were treated with melatonin with dosages ranging from 6.6 g daily for 35 days to daily intravenous injections of 250 mg for 7 days without any obvious undesirable side effects. As noted by Lerner and Nordlund: &dquo;The first person to ever receive 200 mg melatonin intravenously daily for 5 days has no evidence of delayed toxicity 18 years later&dquo; (p. 339). Nowadays, the claims regarding the possible therapeutic proper-ties of melatonin that were popularized by the media have resulted in daily melatonin use by millions.
No doubt, more information is needed on the longterm effects of melatonin treatment during various clinical and treatment conditions. Recent findings from our laboratory demonstrating inverse relationships between gonadotropins and melatonin in patients with pubertal disorders, as well as the identification of luteinizing hormone and folliclestimulating hormone receptors in the human pineal gland , indicate that melatonin plays a role in sex hormone regulation in humans. Thus, we particularly caution against the prolonged use of melatonin during puberty.
